Vaxxitek^® HVT+IBD+ND Designed for you

Strong immune foundation and optimized protection against Marek’s disease (MD), infectious bursal disease (IBD), and Newcastle disease (ND).

VAXXITEK^® HVT+IBD+ND

Designed For You

3-in-1 Protection

Protects against IBD, MD, and ND in a single vaccination.¹
Immune Foundation

Uses the same backbone as VAXXITEK^® HVT+IBD to help you lay a strong immune foundation.^2–9
Early Onset/Long Duration of Immunity

Early onset and long duration of immunity for protection throughout susceptible periods.¹
Potential Performance Benefits

Strong immune foundation enables productivity, reduces antibiotic use, and supports return on investment.^13–18

HOW IT WORKS

1-Proven HVT+IBD platform

It all start with the proven HVT+IBD platform that provides efficient, broad protection against IBD classic and MD.
2-Velogenic ND insert

A fusion gene from the most prevalent and velogenic strains of the ND virus genotype worldwide: genotype VII is inserted into this platform for broad protection against ND viruses. ^19-20
3-Single promoter

The NDV F insertion site is the same as the IBD VP2 gene. The use of a single promotor allows a consistent antigen expression.

SEE VAXXITEK^® HVT+IBD+ND IN ACTION

VAXXITEK^® HBT+IBD+ND PRODUCT INFORMATION

Indication

Recommended for the vaccination of healthy 18- to 19-day-old chicken embryos and day-old chicken against standard and variant bursal disease, Newcastle disease, and Marek’s disease

Dosage

Available in 1000, 2000, 4000 dose ampules in frozen presentation

Safety Information

Do not mix with other products, except as specified on the label
In case of human exposure, contact a physician
Administer only as recommended
Use entire contents when first opened
Do not vaccinate within 21 days before slaughter
Contains penicillin and streptomycin sulfate, which are added as bacteriostatic agents
Contains amphotericin B as a fungistatic agent
Inactivate unused contents before disposal
Safety comparable to existing HVT vector vaccines²¹
Proven to remain safe and stable; will not revert to virulence²²

Download PDF

References: 1. Data on file. Boehringer Ingelheim Animal Health. 2. Hoerr FJ. Clinical aspects of immunosuppression in poultry. Avian Dis. 2010; 54:2–15. 3. Naqi S, Thompson G, Bauman B, Mohammed H. The exacerbating effect of infectious bronchitis virus infection on the infectious bursal disease virus-induced suppression of opsonization by Escherichia coli antibody in chickens. Avian Dis. 2001; 45:52–60. 4. Alonso Castro M, Merino Cabria D, Fernandez Garcia D, Torrubia Diaz J, Herreras Viejo R, Fernandez Revuelta J, Mateo Oyague J, Carvajal Uruena A. Evaluation of the effects of vaccination with a HVT-IBD vector vaccine on bursa Fabricii, production parameters and meat properties in broilers. Abstract presented at the XVIII Congress of the World Veterinary Poultry Association; 2013: Nantes, France. 5. Devaud I, Herin JB, Trotel A, Pagot E, Voisin F. A field study in commercial layers to evaluate the effects of an HVT-IBD vector vaccine on production performances in comparison with a live IBD vaccine. Abstract presented at the XVIII Congress of the World Veterinary Poultry Association; 2013: Nantes, France. 6. Ganapathy K, Wilkins M, Forrester A, Jones RC, Lemiere S. Protection and immune responses against virulent infectious bronchitis viruses in HVT-IBD recombinant or IBD-complex vaccinated broiler chicks. Abstract presented at the First International Respiratory Disease Conference, Athens, United States of America, 2011. 7. Lemiere S, Wilkins M, Forrester A, Jones R, Ganapathy K. Protection and immune responses against virulent infectious bronchitis (IB) viruses in herpesvirus turkey-infectious bursal disease (HVT-IBD) vaccinated broiler chicks. Abstract presented at the XVII Congress of the World Veterinary Poultry Association; 2011: Cancun, Mexico. 8. Rautenschlein S, Lemiere S, Prandini F. Evaluation of the effects of an HVT-IBD vector vaccine on the immune system of layer pullets in comparison with two commercial live IBD vaccines. Abstract presented at the XVIII Congress of the World Veterinary Poultry Association; 2013: Nantes, France. 9. Rautenschlein S, Lemiere S, Simon B, Prandini F. A comparison of the effects on the humoral and cell-mediated immunity between an HVT-IBD vector vaccine and an IBDV immune complex vaccine after in ovo vaccination of commercial broilers. Abstract presented at the XVIII Congress of the World Veterinary Poultry Association; 2013: Nantes, France. 10. Data on File. Study report number 16–191. Merial Select, Inc.; 2017. 11. Data on File. Study report number 16–190. Merial Select, Inc.; 2018. 12. Data on File. Report number 16–0499. Merial Select, Inc.; 2017. 13. Lemiere S, Rojo F, Fernandez R, et al. Benefits of the herpesvirus of turkey vector vaccine of infectious bursal disease in control of immune-depression in broilers and decrease of use of antibiotic medication. Abstract presented at: The XVIII Congress of the World Veterinary Poultry Association; 2013: Nantes, France. 14. Hoelzer K, Bielke L, Blake DP, et al. Vaccines as alternatives to antibiotics for food-producing animals. Part 2: new approaches and potential solutions. Vet Res. 2018;49:70. 15. Atienza JC, Nagera AJ, Martinez PO, et al. Evaluation of a herpesvirus of turkey vector vaccine inducing protection against infectious bursal and Marek’s diseases (VAXXITEK® HVT + IBD) under Philippines field conditions Abstract presented at the XXIII Congress; 29 June 29–July 4, 2008; Queensland, Australia. 16. Rautenschlein S, Lemiere S, Simon B, Prandini F. A comparison of the effects of the humoral and cell-mediated immunity between an HVT-IBD vector vaccine and an IBDV-immune complex vaccine after in ovo vaccination of commercial broilers. Abstract presented at the XVII Congress of the World Veterinary Poultry Association; 2011: Cancun, Mexico. 17. Tang SF, He SJ, Li WM, Lemiere S. Field experience of vaccination in day-old broiler chickens with a herpesvirus turkey-infectious bursal disease (HVT-IBD) vector vaccine in different systems of chicken production across China. Poster presentation. Abstract presented at the XVII Congress of the World Veterinary Poultry Association; 2011: Cancun, Mexico. 18. Zhou X, Wang D, Xiong J, Zhang P, Li Y, She R. Protection of chickens, with or without maternal antibodies, against IBDV infection by a recombinant IBDV-VP2 protein. Vaccine. 2010;28:3990–3996. 19. Miller PJ, Haddas R, Simanov L. Identification of new sub-genotypes of virulent Newcastle disease virus with potential panzootic features. Infect Genet Evol. 2015;29:216–229. 20. Alexander DJ. Newcastle disease and other avian paramyxoviruses. Rev Sci Tech. 2000;19:443–462. 21. Data on File. Study report number 16–187. Merial Select, Inc.; 2017. 22. Data on File. Study report number 17.0107.R. Boehringer Ingelheim R&D,; 2017.

Vaxxitek® HVT+IBD+ND Designed for you